Patents Assigned to Pfizer
  • Methods of treating chronic pain
    Patent number: 8293239
    Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: October 23, 2012
    Assignee: Pfizer Limited
    Inventors: Kristian Todd Poulsen, David Louis Shelton, Joerg Zeller, Ian Machin, Laura Corradini
  • 3-aminocyclopentanecarboxamides as chemokine receptor agonists
    Patent number: 8293903
    Abstract: There is provided a compound of Formula I(a) or I(b) or a pharmaceutically acceptable salt thereof, wherein the various substituents are defined herein.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: October 23, 2012
    Assignee: Pfizer Inc.
    Inventors: Robert O. Hughes, Rajesh V. Devraj, Donald J. Rogier, John I. Trujillo, Steve R. Turner, Wei Huang
  • Method and apparatus for monitoring the performance of automated egg removal
    Patent number: 8292340
    Abstract: Methods and apparatus are provided that automatically determine whether or not eggs designated for removal from an egg carrier have been removed by an egg removal apparatus. Light is emitted along a path above and across an egg carrier as an egg picker moves to pick up an egg. The length of time that the light path is blocked when the egg picker is moved is measured and used to determine whether or not the egg has been removed from the carrier. Another apparatus and method is provided for detecting a malfunctioning egg picker. A detection device detects a number of eggs in the egg carrier. A control device monitors the egg picker and the detection device. The control device calculates the number of eggs in the egg carrier for determining when the number of eggs varies a predetermined amount from an egg count number for the egg carrier.
    Type: Grant
    Filed: September 22, 2008
    Date of Patent: October 23, 2012
    Assignee: Pfizer Inc.
    Inventor: John H. Hebrank
  • Ketoreductase polypeptides and uses thereof
    Patent number: 8288131
    Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of stereo specifically reducing (R)-2-methylpentanal to (R)-2-methylpentanol. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to produce (R)-2-methylpentanol and related compounds.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 16, 2012
    Assignees: Codexis, Inc., Pfizer, Inc.
    Inventors: Rama Voladri, Owen Gooding, Stephan Jenne, Emily Mundorff
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 8288405
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: October 16, 2012
    Assignee: Pfizer Inc.
    Inventors: Scott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
  • CRYSTALLINE PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS
    Publication number: 20120258976
    Abstract: The present invention discloses novel crystalline and non-crystalline forms of 3-((3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip-eridin-1-yl)-3-oxopropionitrile, pharmaceutical composition containing the same, preparations thereof and the uses thereof.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: Pfizer Inc.
    Inventors: Brendan J. Murphy, Timothy D. White, Brian P. Chekal, Phillip J. Johnson, Christopher James Foti, Leonid A. Margulis
  • PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
    Publication number: 20120258950
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: PFIZER LIMITED
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS
    Publication number: 20120259115
    Abstract: This invention relates to methods and intermediates useful for the synthesis of pyrrolo [2,3-d] pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.
    Type: Application
    Filed: June 20, 2012
    Publication date: October 11, 2012
    Applicant: PFIZER INC.
    Inventors: Sally Gut Ruggeri, Joel M. Hawkins, Teresa M. Makowski, Jennifer L. Rutherford, Frank J. Urban
  • Inhibitors of cytosolic phospholipase A
    Patent number: 8283373
    Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: October 9, 2012
    Assignee: Pfizer Inc.
    Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Succinate salt of 2-((4-(1-methyl-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline
    Patent number: 8283471
    Abstract: The present invention relates to a succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: October 9, 2012
    Assignee: Pfizer, Inc.
    Inventors: Caroline Proulx-Lafrance, Patrick Robert Verhoest
  • BENEFICIAL EFFECTS OF COMBINATION THERAPY ON CHOLESTEROL
    Publication number: 20120252825
    Abstract: The present invention discloses pharmaceutical combination therapies for the treatment or prevention of diseases in a mammal comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the same and kits for achieving a therapeutic effect in a mammal comprising pharmaceutical combination therapies are further described.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 4, 2012
    Applicant: Pfizer Inc.
    Inventors: Keith Stuart Kanik, Samuel H. Zwillich, Mary Gardiner Boy
  • SAPONIN ADJUVANT COMPOSITIONS AND METHODS RELATING THERETO
    Publication number: 20120251566
    Abstract: An adjuvant composition which comprises an anionic macromolecule component particularly an ionic polysaccharide such as DEAE-dextran, and a saponin component, particularly an immunostimulating complex component. Immunogenic compositions comprising an immunogen and this adjuvant composition are also disclosed together with methods of use thereof.
    Type: Application
    Filed: March 14, 2012
    Publication date: October 4, 2012
    Applicant: Pfizer Inc.
    Inventor: John Walker
  • Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
    Patent number: 8278457
    Abstract: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: October 2, 2012
    Assignee: Pfizer Inc.
    Inventors: Anton F. J. Fliri, Randall James Gallaschun, Christopher John O'Donnell, Jacob Bradley Schwarz, Barbara E. Segelstein
  • Pyrrolidines
    Patent number: 8278343
    Abstract: This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: October 2, 2012
    Assignee: Pfizer Inc.
    Inventors: Kevin N. Dack, James E. Mills, Sarah E. Skerratt
  • Amino-heterocyclic compounds
    Patent number: 8278295
    Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: October 2, 2012
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Claffey, Christopher J. Helal, Patrick R. Verhoest
  • Bicyclo-pyrazoles and pharmaceutical compositions comprising them
    Patent number: 8273765
    Abstract: Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: September 25, 2012
    Assignee: Pfizer Italia S.R.L.
    Inventors: Daniele Fancelli, Valeria Pittala′, Mario Varasi
  • Anti-IgE vaccines
    Patent number: 8273356
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: September 25, 2012
    Assignee: Pfizer Inc.
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • 4-methylpyridopyrimidinone compounds
    Patent number: 8273755
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 25, 2012
    Assignee: Pfizer Inc
    Inventors: Hengmiao Cheng, Dilip Bhumralkar, Klaus Ruprecht Dress, Jacqui Elizabeth Hoffman, Mary Catherine Johnson, Robert Steven Kania, Phuong Thi Quy Le, Mitchell David Nambu, Mason Alan Pairish, Michael Bruno Plewe, Khanh Tuan Tran
  • 4-1BB BINDING MOLECULES
    Publication number: 20120237498
    Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Application
    Filed: September 9, 2011
    Publication date: September 20, 2012
    Applicant: PFIZER INC
    Inventors: Bianca AHRENS, Sangita M. BAXI, Timothy Scott FISHER, Richard Michael JEROME, Kathrin LADETZKI-BAEHS, Theodore OLIPHANT, Leslie Lynne SHARP, Michael TESAR, Libbey Anne YATES, Moritz ZULLEY
  • Carboxamide derivatives as muscarinic receptor antagonists
    Patent number: 8268881
    Abstract: The invention relates to compounds of formula processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: September 18, 2012
    Assignee: Pfizer Limited
    Inventors: Paul Alan Glossop, Simon John Mantell, Anthony Wood, Christine Anne Louise Watson